Aditxt secures call option to purchase $25M Evofem convertible notes for $13M

Aditxt, Inc.

Aditxt granted call option to acquire Evofem convertible notes (aggregate $25M principal) and purchase rights from Adjuvant funds for $13M.
Option exercisable after Future Pak Note fully repaid, until June 30, 2025; exercise triggers $13M payment.
If Aditxt does not provide $1.5M capital to Evofem by April 30, 2025, Adjuvant may transfer securities without consent.
Evofem consents to assignment of notes and waives opinion of counsel requirements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.